Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
03/09/2026 05:04
BRIEF-BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China Sept 3 (Reuters) - BioArctic AB (publ) BIOAb.ST:
LEQEMBI® SUBCUTANEOUS FORMULATION APPROVED FOR INITIATION TREATMENT IN CHINA
BIOARCTIC AB (PUBL) - LEQEMBI SC-AI LAUNCH IN CHINA PLANNED DURING EISAI FY2026 ENDING MARCH 31, 2027
Source text: ID:nWkrbRJpB3
Further company coverage: [BIOAb.ST]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln